Hikma Pharmaceuticals (HIK) News Today GBX 1,953 +18.00 (+0.93%) (As of 12/20/2024 12:01 PM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsDividendHeadlinesInsider TradesSustainability All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Hikma Pharmaceuticals (LON:HIK) Stock Passes Above 200-Day Moving Average - What's Next?Hikma Pharmaceuticals (LON:HIK) Shares Cross Above Two Hundred Day Moving Average - What's Next?December 17, 2024 | marketbeat.comBTIG Downgrades Carisma Therapeutics (CARM)December 11, 2024 | msn.comHikma Pharmaceuticals (LON:HIK) Stock Price Down 0.5% - Here's WhyHikma Pharmaceuticals (LON:HIK) Stock Price Down 0.5% - Should You Sell?December 7, 2024 | marketbeat.comHikma Pharmaceuticals rises Monday, still underperforms marketNovember 12, 2024 | marketwatch.comEuropean Stocks Close Lower As Markets Assess Rate Moves, EarningsNovember 9, 2024 | markets.businessinsider.comEuropean Stocks Close Lower As Investors React To Earnings, BoE Rate DecisionNovember 8, 2024 | markets.businessinsider.comHikma Pharmaceuticals reiterates full-year guidance amid strong growthNovember 7, 2024 | lse.co.ukEuropean Stocks Fail To Hold Early Gains, Close WeakNovember 6, 2024 | markets.businessinsider.comUnited Kingdom shares lower at close of trade; Investing.com United Kingdom 100 down 0.17%November 5, 2024 | msn.comHikma Pharmaceuticals (LON:HIK) Shares Pass Above 200 Day Moving Average - What's Next?Hikma Pharmaceuticals (LON:HIK) Stock Price Crosses Above 200 Day Moving Average - Should You Sell?October 30, 2024 | marketbeat.comHikma Pharmaceuticals (LON:HIK) Stock Price Crosses Above Two Hundred Day Moving Average - Should You Sell?Hikma Pharmaceuticals (LON:HIK) Share Price Crosses Above Two Hundred Day Moving Average - What's Next?October 22, 2024 | marketbeat.com2024 Research Report | Antipsychotic Drugs Market Poised for Significant Growth by 2030, Advances in Mental Health Treatment Drive DemandOctober 14, 2024 | uk.finance.yahoo.comMajor European Markets Close On Firm NoteOctober 14, 2024 | markets.businessinsider.comGlobal Antiemetics Drugs Market to Exhibit Growth at a CAGR of ~6% by 2030 | DelveInsightOctober 10, 2024 | finance.yahoo.comUK stocks swing into the red as oil prices retreatOctober 8, 2024 | msn.comEuropean Stocks Close Lower On Growth Worries As Markets Await Fresh DataOctober 8, 2024 | markets.businessinsider.comEuropean markets finish lower as car manufacturers struggleSeptember 30, 2024 | msn.comU.K. stocks lower at close of trade; Investing.com United Kingdom 100 down 1.05%September 30, 2024 | msn.comHikma Pharmaceuticals PLC (LON:HIK) Receives Consensus Recommendation of "Moderate Buy" from AnalystsShares of Hikma Pharmaceuticals PLC (LON:HIK - Get Free Report) have earned a consensus rating of "Moderate Buy" from the six research firms that are currently covering the company, MarketBeat reports. Two equities research analysts have rated the stock with a hold rating and four have given a buySeptember 26, 2024 | marketbeat.comWith 55% ownership, Hikma Pharmaceuticals PLC (LON:HIK) boasts of strong institutional backingSeptember 25, 2024 | finance.yahoo.comHikma Pharmaceuticals (LON:HIK) Stock Price Passes Above Two Hundred Day Moving Average of $1,917.24Hikma Pharmaceuticals (LON:HIK) Share Price Passes Above 200 Day Moving Average of $1,917.24September 21, 2024 | marketbeat.comGlobal stocks rise as investors hopeful of US interest rate cutSeptember 18, 2024 | msn.comUnited Kingdom shares higher at close of trade; Investing.com United Kingdom 100 up 0.37%September 17, 2024 | msn.comHikma Pharmaceuticals (LON:HIK) Sets New 12-Month Low at $559.00Hikma Pharmaceuticals (LON:HIK) Sets New 52-Week Low at $559.00September 13, 2024 | marketbeat.comUS Allows ADHD Drugmaker To Increase Production Limit To Ease Ongoing ShortageSeptember 6, 2024 | msn.comHikma Pharmaceuticals (LON:HIK) shareholders have endured a 17% loss from investing in the stock three years agoSeptember 4, 2024 | finance.yahoo.comHikma Pharmaceuticals falls Tuesday, still outperforms marketSeptember 3, 2024 | marketwatch.comLONDON BROKER RATINGS: Berenberg raises Hikma Pharmaceuticals to 'buy'September 3, 2024 | lse.co.ukHikma Pharmaceuticals (LON:HIK) Stock Crosses Above 200-Day Moving Average of $1,921.05Hikma Pharmaceuticals (LON:HIK) Share Price Passes Above Two Hundred Day Moving Average of $1,921.05August 29, 2024 | marketbeat.comHikma Pharmaceuticals (LON:HIK) Stock Price Passes Above Two Hundred Day Moving Average of $1,917.25Hikma Pharmaceuticals (LON:HIK) Stock Crosses Above 200-Day Moving Average of $1,917.25August 21, 2024 | marketbeat.comHikma Pharmaceuticals (LON:HIK) PT Raised to GBX 2,100Berenberg Bank raised their target price on shares of Hikma Pharmaceuticals from GBX 2,000 ($25.54) to GBX 2,100 ($26.81) and gave the stock a "hold" rating in a report on Monday.August 13, 2024 | marketbeat.comFTSE outperforms European peers after oil prices riseAugust 12, 2024 | msn.comFTSE 100 Rises Ahead Of Key Economic DataAugust 12, 2024 | markets.businessinsider.comHikma Pharmaceuticals falls Monday, underperforms marketAugust 12, 2024 | marketwatch.comHikma Pharmaceuticals First Half 2024 Earnings: Beats ExpectationsAugust 11, 2024 | finance.yahoo.comHikma Pharmaceuticals PLC Just Beat EPS By 12%: Here's What Analysts Think Will Happen NextAugust 11, 2024 | finance.yahoo.comLondon's FTSE 100 inches lower as companies trade ex-dividend; earnings cap declinesAugust 8, 2024 | msn.comSTOXX 600 recovers early losses on US jobs data reliefAugust 8, 2024 | msn.comLondon's FTSE 100 ends lower as top companies trade ex-dividendAugust 8, 2024 | msn.comHikma Pharmaceuticals PLC Declares Dividend of $0.32 (LON:HIK)Hikma Pharmaceuticals PLC (LON:HIK) declared a dividend on Thursday, August 8th. Investors of record on Thursday, August 15th will be given a dividend of $0.32 per share on Friday, September 20th. This represents a yield of 1.37%. The ex-dividend date is Thursday, August 15th. The official announcement can be seen at this link.August 8, 2024 | marketbeat.comHikma Pharmaceuticals (LON:HIK) Stock Price Crosses Above 200 Day Moving Average of $1,912.86Hikma Pharmaceuticals (LON:HIK) Stock Price Crosses Above 200-Day Moving Average of $1,912.86July 31, 2024 | marketbeat.comHikma Pharmaceuticals (LON:HIK) Stock Price Passes Above Two Hundred Day Moving Average of $1,903.43Hikma Pharmaceuticals (LON:HIK) Shares Pass Above 200 Day Moving Average of $1,903.43June 26, 2024 | marketbeat.comHikma Pharmaceuticals PLC (LON:HIK) Receives Average Recommendation of "Hold" from BrokeragesShares of Hikma Pharmaceuticals PLC (LON:HIK - Get Free Report) have been assigned an average recommendation of "Hold" from the five ratings firms that are currently covering the firm, MarketBeat.com reports. Three analysts have rated the stock with a hold rating and two have given a buy rating toJune 18, 2024 | marketbeat.comHikma Pharmaceuticals' (HIK) "Buy" Rating Reaffirmed at Deutsche Bank AktiengesellschaftDeutsche Bank Aktiengesellschaft reaffirmed a "buy" rating and issued a GBX 2,750 ($34.94) target price on shares of Hikma Pharmaceuticals in a research report on Tuesday.June 18, 2024 | marketbeat.comHikma Pharmaceuticals (LON:HIK) Shares Cross Above Two Hundred Day Moving Average of $1,889.51Hikma Pharmaceuticals (LON:HIK) Stock Price Passes Above 200 Day Moving Average of $1,889.51June 14, 2024 | marketbeat.comHikma Pharmaceuticals (LON:HIK) Share Price Crosses Above Two Hundred Day Moving Average of $1,873.97Hikma Pharmaceuticals (LON:HIK) Stock Passes Above 200-Day Moving Average of $1,873.97May 29, 2024 | marketbeat.comActive Pharmaceutical Ingredient Market Worth $238.3 billion | MarketsandMarketsMay 17, 2024 | finanznachrichten.deHikma Pharmaceuticals PLC (LON:HIK) Insider Buys £14,565.44 in StockMay 10, 2024 | insidertrades.comHikma Pharmaceuticals' (HIK) Equal Weight Rating Reaffirmed at BarclaysBarclays reiterated an "equal weight" rating and issued a GBX 2,000 ($25.13) price objective on shares of Hikma Pharmaceuticals in a research report on Tuesday.May 7, 2024 | marketbeat.comEuropean Stocks Close On Strong Note As Investors Cheer Earnings UpdatesApril 26, 2024 | markets.businessinsider.com Get Hikma Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for HIK and its competitors with MarketBeat's FREE daily newsletter. Email Address Why I'm telling friends to avoid gold stocks (Ad)Back in November, gold made a tiny move of 1.6%. But according to my backtesting by using a special type of gold trade, I would have seen a 141% gain in just a week. It happened again in March. Gold nudged up 1.2%. This time? A 104% overnight gain. And in June? A 1% gold move turned into a 74% gain in two weeks. Granted, there would have been smaller wins and those that did not work out, but you see, there's a reason I'm telling all my friends to hold off from buying gold or regular gold stocks right now. There's a more lucrative way to play the gold market as we enter a new breakout period. It's all about catching what I call "Acceleration Cycles." And if you’d like to get your hands on this, here you go, the complete breakdown. HIK Media Mentions By Week HIK Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. HIK News Sentiment▼0.370.59▲Average Medical News Sentiment HIK News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. HIK Articles This Week▼11▲HIK Articles Average Week Get Hikma Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for HIK and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies HUTCHMED News Indivior News Allergy Therapeutics News Alliance Pharma News Beximco Pharmaceuticals News Animalcare Group News ECO Animal Health Group News Shield Therapeutics News Celadon Pharmaceuticals News Chill Brands Group News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (LON:HIK) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersThis Crypto Is Set to Explode in DecemberIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredAI breakthrough about to upend industryEveryone is talking about AI right now. The talk has been endless ever since ChatGPT was released to the m...Porter & Company | SponsoredNvidia’s Bold Move: Tackling Tech’s $1 Trillion CrisisTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | SponsoredYour bank is lying to you.You might think you have your money in a high-yield savings account, but do you really? The national average A...MyBankTracker | SponsoredMUST SEE: The most important video in the world right now?If you have a significant amount of money in the stock market right now — or if you're sitting on the sideline...InvestorPlace | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Hikma Pharmaceuticals PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share Hikma Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
